Leslie M. Randall, MD, MAS, discusses the unmet needs in platinum-resistant ovarian cancer.
Leslie M. Randall, MD, MAS, professor, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Massey Cancer Center, VCU Health, discusses the unmet needs in platinum-resistant ovarian cancer.
Limited treatment options are available for patients with platinum-resistant ovarian cancer, representing a clear unmet need, explains Randall.
Although chemotherapy is the standard of care, the response rate is approximately 15% in this setting, says Randall.
As such, the FDA accelerated approval pathway, which offers a potential opportunity to fulfill these unmet needs, still stands in the United States, Randall concludes.